Simultaneous Accelerated Corneal Crosslinking and Laser In situ Keratomileusis for the Treatment of High Myopia in Asian Eyes.

IF 0.4 Q4 OPHTHALMOLOGY Open Ophthalmology Journal Pub Date : 2018-07-23 eCollection Date: 2018-01-01 DOI:10.2174/1874364101812010143
Jin Rong Low, Li Lim, Jane Chwee Wah Koh, Daniel Kai Peng Chua, Mohamad Rosman
{"title":"Simultaneous Accelerated Corneal Crosslinking and Laser <i>In situ</i> Keratomileusis for the Treatment of High Myopia in Asian Eyes.","authors":"Jin Rong Low,&nbsp;Li Lim,&nbsp;Jane Chwee Wah Koh,&nbsp;Daniel Kai Peng Chua,&nbsp;Mohamad Rosman","doi":"10.2174/1874364101812010143","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>LASIK Xtra is a recently described technique which combines LASIK and accelerated corneal cross-linking(CXL) in the same setting. Its long-term outcome in Asians with high myopia is not well described.</p><p><strong>Objectives: </strong>To compare the efficacy, predictability and safety of LASIK Xtra with LASIK in patients with high myopia.</p><p><strong>Method: </strong>This is a retrospective study comparing 50 consecutive eyes undergoing LASIK Xtra for the correction of high myopia and/or myopic astigmatism (-6.63 to -15.50 D manifest spherical equivalent) with a matched control group of 50 eyes undergoing LASIK alone for correction of high myopia (-6.00 to -12.25 D manifest spherical equivalent). Mean follow-up was 5.7 months (range, 1.5-13.3 months) for LASIK Xtra and 3.6 months (range, 1.7-4.2 months) for LASIK only. Outcome measures included Uncorrected Distance Visual Acuity (UDVA), Corrected Distance Visual Acuity (CDVA), refraction and intraoperative and postoperative complications.</p><p><strong>Results: </strong>At post-operative 3 months, all eyes achieved UDVA of 20/40 or better, and 80.0% of LASIK Xtra eyes achieved UDVA of 20/20 or better, compared to 66.0% of LASIK only eyes (<i>p</i> = 0.115). Efficacy indices were 0.99±0.17 for LASIK Xtra and 0.94±0.17 for LASIK only (<i>p</i> = 0.164). The proportion of eyes within ±0.50 D of attempted correction was 84% in the LASIK only group and 72% in the LASIK Xtra group at post-operative 3 months (<i>p</i> = 0.148). Safety indices were 1.11±0.19 and 1.11±0.18 in the LASIK Xtra and LASIK only groups, respectively (<i>p</i> = 0.735).</p><p><strong>Conclusion: </strong>LASIK Xtra achieved comparable safety, predictability and efficacy as LASIK in patients with high myopia. Good refractive stability was attained at 6-12 months. Further long term studies are required to determine whether simultaneous CXL is able to reduce postoperative LASIK keratectasia in high-risk individuals.</p>","PeriodicalId":46347,"journal":{"name":"Open Ophthalmology Journal","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2018-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874364101812010143","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Ophthalmology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874364101812010143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: LASIK Xtra is a recently described technique which combines LASIK and accelerated corneal cross-linking(CXL) in the same setting. Its long-term outcome in Asians with high myopia is not well described.

Objectives: To compare the efficacy, predictability and safety of LASIK Xtra with LASIK in patients with high myopia.

Method: This is a retrospective study comparing 50 consecutive eyes undergoing LASIK Xtra for the correction of high myopia and/or myopic astigmatism (-6.63 to -15.50 D manifest spherical equivalent) with a matched control group of 50 eyes undergoing LASIK alone for correction of high myopia (-6.00 to -12.25 D manifest spherical equivalent). Mean follow-up was 5.7 months (range, 1.5-13.3 months) for LASIK Xtra and 3.6 months (range, 1.7-4.2 months) for LASIK only. Outcome measures included Uncorrected Distance Visual Acuity (UDVA), Corrected Distance Visual Acuity (CDVA), refraction and intraoperative and postoperative complications.

Results: At post-operative 3 months, all eyes achieved UDVA of 20/40 or better, and 80.0% of LASIK Xtra eyes achieved UDVA of 20/20 or better, compared to 66.0% of LASIK only eyes (p = 0.115). Efficacy indices were 0.99±0.17 for LASIK Xtra and 0.94±0.17 for LASIK only (p = 0.164). The proportion of eyes within ±0.50 D of attempted correction was 84% in the LASIK only group and 72% in the LASIK Xtra group at post-operative 3 months (p = 0.148). Safety indices were 1.11±0.19 and 1.11±0.18 in the LASIK Xtra and LASIK only groups, respectively (p = 0.735).

Conclusion: LASIK Xtra achieved comparable safety, predictability and efficacy as LASIK in patients with high myopia. Good refractive stability was attained at 6-12 months. Further long term studies are required to determine whether simultaneous CXL is able to reduce postoperative LASIK keratectasia in high-risk individuals.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
加速角膜交联联合激光原位角膜磨镶术治疗亚洲人高度近视。
背景:LASIK Xtra是一种结合LASIK和加速角膜交联(CXL)的新技术。它在亚洲高度近视患者中的长期效果尚未得到很好的描述。目的:比较LASIK Xtra与LASIK在高度近视患者中的疗效、可预测性和安全性。方法:这是一项回顾性研究,比较50只连续接受LASIK额外矫正高度近视和/或近视散光的眼睛(-6.63至-15.50 D显球当量)和50只单独接受LASIK矫正高度近视的眼睛(-6.00至-12.25 D显球当量)。LASIK Xtra的平均随访时间为5.7个月(1.5-13.3个月),仅LASIK的平均随访时间为3.6个月(1.7-4.2个月)。结果测量包括未矫正距离视力(UDVA)、矫正距离视力(CDVA)、屈光和术中及术后并发症。结果:术后3个月,所有眼UDVA均达到20/40及以上,其中80.0%的LASIK +眼UDVA达到20/20及以上,66.0%的LASIK +眼UDVA达到20/20及以上(p = 0.115)。LASIK Xtra组疗效指数为0.99±0.17,单纯LASIK组疗效指数为0.94±0.17 (p = 0.164)。术后3个月,仅LASIK组在±0.50 D内尝试矫正的眼睛比例为84%,LASIK +组为72% (p = 0.148)。LASIK +组和纯LASIK组的安全性指数分别为1.11±0.19和1.11±0.18 (p = 0.735)。结论:LASIK Xtra在高度近视患者中具有与LASIK相当的安全性、可预测性和有效性。6-12个月时获得良好的屈光稳定性。需要进一步的长期研究来确定同时进行CXL是否能够减少高危人群术后LASIK角膜扩张症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
24
期刊介绍: The Open Ophthalmology Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in ophthalmology, including use of ophthalmological therapies, devices and surgical techniques. The Open Ophthalmology Journal, a peer-reviewed journal, is an important and reliable source of current information on developments in the field. The emphasis will be on publishing quality papers rapidly and making them freely available to researchers worldwide.
期刊最新文献
A Narrative Review of Morquio Syndrome: Mucopolysaccharidosis (MPS) Type IV MGrx - A Novel Multi-modal Thermal Device for Treating Moderate to Severe Meibomian Gland Dysfunction and Dry Eye Determinants of Refractive Errors on School-going Children Attending Ophthalmic Clinic of AlMoosa Hospital in Saudi Arabia A Systematic Review and Meta-analysis of Convergence Insufficiency Prevalence and Management Options Photodynamic and Anti-VEGF Therapy for Polypoidal Choroidal Vasculopathy - ‘Real World’ Outcomes in a Caucasian Population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1